Douglas J. Williamson - 10 Feb 2023 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
Executive VP, Research & Dev
Signature
/s/ Austin D. Kim, Attorney-in-Fact
Issuer symbol
ACAD
Transactions as of
10 Feb 2023
Net transactions value
$0
Form type
4
Filing time
13 Feb 2023, 17:45:02 UTC
Previous filing
13 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Non-Qualified Stock Option (Right to Buy) Award $0 +237,296 $0.000000 237,296 10 Feb 2023 Common Stock 237,296 $18.97 Direct F1
transaction ACAD Restricted Stock Units Award $0 +50,655 $0.000000 50,655 10 Feb 2023 Common Stock 50,655 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the stock option vest on the first anniversary of February 10, 2023, with the balance vesting in 36 equal monthly installments thereafter, such that the shares subject to the option will be fully vested on the fourth anniversary of such date.
F2 Each restricted stock unit is subject to the 2023 Inducement Plan and represents a contingent right to receive one share of Acadia common stock.
F3 50% of the shares subject to the restricted stock units vest on the second anniversary of February 10, 2023, with the balance vesting in two equal annual installments thereafter, such that the shares subject to the restricted stock units will be fully vested on the fourth anniversary of such date.